Ratings Change: Agios Pharmaceuticals (NASDAQ:AGIO) Is Now Covered By Oppenheimer. What to Expect?

November 29, 2016 - By Winifred Garcia

Ratings Change: Agios Pharmaceuticals (NASDAQ:AGIO) Is Now Covered By Oppenheimer. What to Expect?

How Oppenheimer Rates Agios Pharmaceuticals (NASDAQ:AGIO)

Oppenheimer issued “Perform” rating on Agios Pharmaceuticals (NASDAQ:AGIO). The firm has started coverage on shares of AGIO in analysts note issued to investors and clients on Tuesday, 29 November.

Agios Pharmaceuticals Inc (NASDAQ:AGIO) Ratings Coverage

Out of 12 analysts covering Agios Pharmaceuticals (NASDAQ:AGIO), 7 rate it a “Buy”, 0 “Sell”, while 5 “Hold”. This means 58% are positive. $132 is the highest target while $47 is the lowest. The $71.73 average target is 17.65% above today’s ($60.97) stock price. Agios Pharmaceuticals has been the topic of 20 analyst reports since July 23, 2015 according to StockzIntelligence Inc. The rating was initiated by Credit Suisse on Thursday, January 21 with “Outperform”. The rating was initiated by Janney Capital on Wednesday, March 2 with “Neutral”. The firm has “Neutral” rating by BTIG Research given on Friday, August 19. SunTrust initiated Agios Pharmaceuticals Inc (NASDAQ:AGIO) on Wednesday, March 30 with “Buy” rating. On Monday, June 13 the stock rating was upgraded by Canaccord Genuity to “Buy”. Leerink Swann downgraded Agios Pharmaceuticals Inc (NASDAQ:AGIO) on Monday, December 7 to “Market Perform” rating. The firm has “Hold” rating given on Wednesday, August 5 by Roth Capital. The firm has “Outperform” rating by Northland Capital given on Thursday, July 23. Needham initiated Agios Pharmaceuticals Inc (NASDAQ:AGIO) rating on Monday, October 24. Needham has “Buy” rating and $60 price target. The rating was maintained by Roth Capital on Monday, November 9 with “Neutral”.

About 356,147 shares traded hands. Agios Pharmaceuticals Inc (NASDAQ:AGIO) has risen 16.58% since April 26, 2016 and is uptrending. It has outperformed by 11.32% the S&P500.

Analysts await Agios Pharmaceuticals Inc (NASDAQ:AGIO) to report earnings on February, 16. They expect $-1.37 EPS, down 26.85% or $0.29 from last year’s $-1.08 per share. After $-1.63 actual EPS reported by Agios Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts -15.95% EPS growth.

Insitutional Activity: The institutional sentiment increased to 1.72 in Q2 2016. Its up 0.33, from 1.39 in 2016Q1. The ratio improved, as 22 funds sold all Agios Pharmaceuticals Inc shares owned while 37 reduced positions. 18 funds bought stakes while 64 increased positions. They now own 35.06 million shares or 11.59% more from 31.42 million shares in 2016Q1.

The Illinois-based Balyasny Asset Management Limited has invested 0.09% in Agios Pharmaceuticals Inc (NASDAQ:AGIO). Alps Advsrs owns 53,272 shares or 0.02% of their US portfolio. Credit Suisse Ag has 99,887 shares for 0% of their US portfolio. Capital Fund has 0.01% invested in the company for 29,847 shares. State Board Of Administration Of Florida Retirement Systems holds 0% of its portfolio in Agios Pharmaceuticals Inc (NASDAQ:AGIO) for 35,008 shares. First Trust Advsrs Ltd Partnership last reported 0.08% of its portfolio in the stock. Creative Planning last reported 8,179 shares in the company. Bessemer Group has 107 shares for 0% of their US portfolio. Geode Cap Limited Liability Co accumulated 0% or 184,770 shares. Nuveen Asset Management Ltd Liability Corporation has 12,250 shares for 0% of their US portfolio. Nationwide Fund Advsr holds 0% of its portfolio in Agios Pharmaceuticals Inc (NASDAQ:AGIO) for 4,604 shares. Baker Bros L P reported 207,915 shares or 0.09% of all its holdings. State Street Corporation last reported 899,186 shares in the company. Amer Group Inc owns 700 shares or 0% of their US portfolio. Moreover, Bancshares Of New York Mellon has 0% invested in Agios Pharmaceuticals Inc (NASDAQ:AGIO) for 108,966 shares.

Insider Transactions: Since June 8, 2016, the stock had 0 buys, and 9 sales for $5.18 million net activity. Shares for $1.79 million were sold by Biller Scott on Wednesday, June 8. Cantley Lewis Clayton Jr. sold $135,404 worth of Agios Pharmaceuticals Inc (NASDAQ:AGIO) on Tuesday, September 27.

Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The company has a market cap of $2.45 billion. The Firm is engaged in the discovery and development of orally available small molecule medicines for the treatment of cancer and rare genetic disorders , which are a subset of orphan genetic metabolic diseases. It currently has negative earnings. The Company’s cancer product candidates are AG-221 and AG-120, which targets mutated isocitrate dehydrogenase 2 and 1, or IDH2 and IDH1, respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

According to Zacks Investment Research, “Agios Pharmaceuticals, Inc. is a biopharmaceutical company. It discovers and develops therapeutics in the field of cancer metabolism and inborn errors of metabolism. The Company’s products include AG-221, AG-120, enzyme glutaminase and AG-348. Agios Pharmaceuticals, Inc. is based in Cambridge, Massachusetts.”

AGIO Company Profile

Agios Pharmaceuticals, Inc., incorporated on August 7, 2007, is a biopharmaceutical company. The Firm is engaged in the discovery and development of orally available small molecule medicines for the treatment of cancer and rare genetic disorders (RGDs), which are a subset of orphan genetic metabolic diseases. The Company’s cancer product candidates are AG-221 and AG-120, which targets mutated isocitrate dehydrogenase 2 and 1, or IDH2 and IDH1, respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2. These mutations are found in a range of hematological malignancies and solid tumors. The lead product candidate in its RGD programs, AG-348, which targets pyruvate kinase-R for the treatment of pyruvate kinase deficiency.

More notable recent Agios Pharmaceuticals Inc (NASDAQ:AGIO) news were published by: Fool.com which released: “Why Agios Pharmaceuticals Inc Stock Skyrocketed Today” on September 07, 2016, also Fool.com with their article: “3 Big Reasons Agios Pharmaceuticals, Inc. Has Plunged 38% in 2016” published on July 03, 2016, Fool.com published: “Why Agios Pharmaceuticals Inc. Presented Lower Today” on June 09, 2016. More interesting news about Agios Pharmaceuticals Inc (NASDAQ:AGIO) were released by: Fool.com and their article: “The Silly Reason Why Agios Pharmaceuticals Inc. Was Clobbered in January” published on February 06, 2016 as well as Fool.com‘s news article titled: “A Short Squeeze and the Rumor Mill Stir Up Agios Pharmaceuticals, Inc. in April” with publication date: May 06, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Tags: , ,

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>